Thoratec VAD
|
|
Thoratec IVAD |
HeartMate II |
|
HeartMate III |
|
|
Our technology for the treatment of heart failure remains unmatched in the
marketplace—nearly 8,000 of our devices have been implanted, four times
that of any other device company. At the same time, no other company can
match our broad product line or proven track record in getting devices approved
and into the market.
Our pioneering efforts include the Thoratec VAD, the first biventricular
support device approved for bridge- to-transplantation, and the HeartMate,
the first assist device approved for Destination Therapy. But being first
is not the ultimate goal—being the best is. With a research and development
team that possesses more than 400 cumulative years of heart assist device
experience, we are making significant progress on our strategy to bring
to market devices that are smaller, offer increased reliability and provide
longer-term support.
Our European approval and FDA filing for U.S. approval for the Thoratec
Implantable VAD (IVAD) reflected a very successful clinical trial involving
approximately nine years of cumulative patient experience.
We also received home discharge approval in the U.S. for the TLC-II Portable
VAD Driver during the year. It provides patients improved quality of life
and can lessen the cost of their care by enabling them to recover at home.
The Company’s HeartMate II represents a quantum leap in technology
as a small, rotary flow device that is designed to support patients for
5-7 years. Initial results from our current safety and efficacy trial have
been encouraging.
We also made measurable strides in the development of the HeartMate III,
a centrifugal flow pump that features a magnetically levitated bearingless
system designed to provide support in excess of 10 years.
|
